Kiniksa Pharmaceuticals International (KNSA) Assets Average (2018 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Assets Average for 9 consecutive years, with $860.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets Average rose 36.57% year-over-year to $860.7 million; the trailing twelve-month figure through Jun 2026 stood at $860.7 million (up 36.57% YoY), and the FY2025 full-year result was $672.1 million, up 21.44% from the prior year.
• Assets Average advanced to $860.7 million in Q2 2026 per KNSA's latest filing, from $794.5 million in the prior quarter.
• Across five years, Assets Average topped out at $860.7 million in Q2 2026 and bottomed at $220.8 million in Q2 2022.
• Historically, Assets Average has averaged $534.5 million across 5 years, with a median of $527.0 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Assets Average decreased 29.8% in 2022, then surged 109.99% in 2023.
• Over 5 years, Assets Average stood at $459.8 million in 2022, then climbed by 9.76% to $504.7 million in 2023, then rose by 12.53% to $567.9 million in 2024, then grew by 29.94% to $738.0 million in 2025, then increased by 16.63% to $860.7 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $860.7 million, $794.5 million, and $738.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.